DEX

DexTech Medical AB is a Swedish clinical-stage biotechnology company specializing in urological oncology, with a primary focus on developing innovative treatments for castration-resistant prostate cancer (CRPC). The company utilizes its proprietary GuaDex technology platform, a water-soluble dextran-based carrier system, to create targeted therapies that improve the delivery and efficacy of active pharmaceutical ingredients. Its lead candidate, OsteoDex, has successfully completed Phase 2b clinical trials for the treatment of bone metastases in mCRPC patients, demonstrating significant potential to inhibit tumor growth in the skeleton with a favorable safety profile. DexTech's pipeline also includes SomaDex, a somatostatin-based therapy for neuroendocrine tumors, and CatDex, an instillation treatment for bladder cancer. Founded by researchers from the Karolinska Institutet, DexTech operates as a virtual company, leveraging strategic partnerships to advance its candidates toward licensing and commercialization.